Learn More
Despite progress in leukemia therapy, most children who experience relapse have a dismal prognosis. New, effective approaches are needed. We conducted a phase 1 study of a novel nucleoside analog, clofarabine, in pediatric patients with refractory and relapsed leukemia. Clofarabine was infused intravenously over 1 hour each day for 5 days. Six dose levels,(More)
PURPOSE A neutropenic diet is often used to prevent infection in patients with acute myeloid leukemia (AML). Although such a diet potentially entails inconvenience, its value is uncertain. PATIENTS AND METHODS One hundred fifty-three patients admitted to a high-efficiency particulate air-filtered room (protected environment [PE]) to receive induction(More)
Malakoplakia is an unusual chronic inflammatory disease occurring predominantly in the bladder and only rarely affecting other organs. For the urinary tract, its aetiology has been ascribed to the presence of Escherichia coli, while the very few cases of cerebral malakoplakia which have been reported so far, have mostly occurred in infants in the clinical(More)
BACKGROUND The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation. It is unclear in the literature whether the outcome of hypocellular acute myeloid leukemia differs from that of(More)
Letter to Editor Recurrent pathogenic mutations in IDH1 and IDH2 at the conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 occur in approximately 20% of patients with acute myeloid leukemia (AML).(1) A recent analysis of AML patients at our institution identified IDH1/2 mutations in 20% (n=167) of 826 AML patients, with IDH1/2 mutations occurring(More)
  • 1